文献速递前列腺癌

恩杂鲁胺与阿比特龙时代骨靶向治疗对转移性去势抵抗性前列腺癌骨相关事件的影响

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-09-03

这项单中心回顾性队列研究纳入2007至2017年249例转移性去势抵抗性前列腺癌(mCRPC)骨转移患者,评估骨靶向治疗(BTT)使用模式及其与骨相关事件(SRE)和总生存(OS)的关联。中位随访7.7年,多因素分析显示,诊断mCRPC时骨转移灶≥4个且一线接受阿比特龙或恩杂鲁胺联合BTT的患者,发生SRE风险降低42%(HR 0.58;95%CI 0.36-0.95),但骨转移灶1-3个者未见此效应,且BTT未改善OS。

要点

  • 骨转移灶≥4个的mCRPC患者,一线阿比特龙或恩杂鲁胺联合BTT可降低SRE风险。
  • 骨转移灶1-3个的患者未观察到BTT预防SRE的获益。
  • BTT的使用与总生存无差异。

核心结论

  • 对于有至少4个骨转移灶的mCRPC患者,早期联合使用抗骨吸收BTT与延长生命的CRPC治疗可能带来SRE预防获益。

研究设计与样本

  • 单中心回顾性队列研究,纳入2007至2017年249例mCRPC骨转移患者,中位随访7.7年(95%CI 5.7-10.2)。

主要发现

  • 诊断mCRPC时骨转移灶≥4个且一线接受阿比特龙或恩杂鲁胺联合BTT的患者,发生SRE风险降低42%(HR 0.58;95%CI 0.36-0.95),对比从未接受BTT或二线接受BTT者。
  • 骨转移灶1-3个的患者中未观察到BTT对SRE风险的类似效应。
  • 接受BTT(无论是否一线联合)的患者未观察到OS差异。

临床怎么用

  • 对于诊断mCRPC时骨转移灶≥4个的患者,可考虑早期联合抗骨吸收BTT与阿比特龙或恩杂鲁胺以预防SRE。
  • 对于骨转移灶1-3个的患者,BTT预防SRE的获益未得到证实,需个体化决策。

局限性

  • 研究为单中心回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS: To assess practice patterns of BTT use and its associations with clinical outcomes in a high-volume center in the modern era of metastatic CRPC management, a retrospective cohort of patients treated for mCRPC with BM between 2007 and 2017 was identified from a single institutions clinical research database. Study endpoints included time from the diagnosis of CRPC to the onset of SRE or OS. Cox proportional hazards model assessed association of BTT use with time to first SRE and OS. RESULTS: In total, 249 patients were identified; median follow-up was 7.7 (95%CI: 5.7-10.2) years. On multivariable analysis, patients with 4 or more BM at diagnosis of mCRPC who received BTT with abiraterone acetate or enzalutamide as first line therapy had a 42% reduced risk of developing an SRE (HR 0.58; 95%CI: 0.36-0.95) compared to those who never received BTT or received it in second line. No such effect was observed in patients with 1-3 BM. No OS difference was noted in patients who received BTT, whether with first line therapy or without. This study is limited by retrospective nature at a single institution. CONCLUSIONS: Our hospital registry data indicate a potential benefit in terms of SRE prevention for early use of antiresorptive BTT in combination with life prolonging CRPC therapies for patients with CRPC and at least 4 BM.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. McGregor B, Zhang L, Gray KP, et al. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. 2020. PMID: 32884090. doi:10.1038/s41391-020-00280-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。